Are Peptides Legal? What "Research Use Only" Actually Means

If you only want the short version. Four different questions share one word, and they have different answers.

Is it FDA approved? For most peptides, no. Can a pharmacy compound it? For a few, yes. Is it legal to sell for human use? Almost never. Is it illegal for you to have? Genuinely unsettled, and not the same as legal.

"Research use only" does not change any of that. Under federal law a product is a drug based on what it is intended for, and the FDA reads intent from the whole page: the claims, the dosing instructions, the syringes sold alongside, the testimonials.

If you compete in tested sport, a fifth question overrides all four, and the answer there is clear and unfavourable.

There is no single answer, because there is no single question.

"Is this peptide legal" is at least four questions wearing one coat, and they have different answers. A compound can be unapproved, un-compoundable, and illegal to sell, while being sold on twenty websites right now, and none of that is a contradiction once you can see the four questions separately.

This is not legal advice. It is a description of how the rules work, so the regulatory note on every compound page means something to you. It describes United States law, with a short section on elsewhere near the end.

The four questions

Is it an approved drug? Has it been through the FDA and received approval for a specific use. Semaglutide has. BPC-157 has not. Most people think this is the only question.

Can a pharmacy compound it? A separate track with its own list, its own rules, and its own committee. A compound can fail the first question and still pass this one. Sermorelin does exactly that.

Is it legal to sell? Almost always no for anything unapproved, and this is where nearly all of the FDA's attention goes.

Is it illegal for me to have? A genuinely different question with a genuinely different answer, and the one everybody actually wants answered. It comes last here because it only makes sense after the others.

And if you compete in anything drug-tested, there is a fifth question that overrides all four, which is covered further down.

The definition that decides everything

Here is the piece that makes the rest make sense, and almost nobody explains it.

Under the Federal Food, Drug and Cosmetic Act, section 201(g)(1), something becomes a drug when it is intended for use in diagnosing, curing, treating or preventing disease, or when it is intended to affect the structure or any function of the body.¹

The second phrase is the one that matters most for peptides, because it captures compounds that make no disease claim at all.

Read that again and notice what is missing. Nothing about the molecule. Nothing about how it was made, how pure it is, or whether it works. The definition turns entirely on what it is intended for.

Then section 505(a) makes it illegal to sell a new drug across state lines without FDA approval.

Put those together and the whole system falls out. The same white powder is a drug or is not a drug depending on what someone intends to do with it. That means the legal question is not really about chemistry at all. It is about intent, and intent has to be established from somewhere.

Where "research use only" comes from, and why it does not work

If a drug is defined by intended use, then labelling a product for laboratory research is an attempt to declare a different intent. "Research use only" rests entirely on that theory.

It is a reasonable-sounding theory and it fails in practice, because the FDA does not take the label's word for it. The FDA works intent out from everything around the product: what the page claims, what the label says, what is sold alongside it, and how it is advertised.¹

So the disclaimer in the footer is one piece of evidence about intent, and everything else on the page is also evidence, and the everything else usually wins.

What the agency counts as evidence

This is worth knowing precisely, because it is a checkable list you can apply to any vendor site.

In warning letters, the FDA has pointed to product pages describing effects on appetite, insulin sensitivity, fat oxidation, weight management and metabolic regulation. It has pointed to dosing instructions. It has pointed to bacteriostatic water and syringes sold alongside the vial. It has pointed to customer testimonials describing personal use.²

None of those are the label. All of them are evidence about who the product is for.

A June 2026 warning letter puts the position in the agency's own words: despite statements on the product labelling marketing the products for "RESEARCH USE ONLY" and "not for human consumption," evidence obtained from the product labelling, including the website, establishes that the products are intended to be drugs for human use.³

That letter concerned Prostamax and Gonadorelin. Both are compounds in this library, which is a useful reminder that this is not a rule about a handful of famous weight-loss drugs.

The disclaimer can make things worse

A quieter point that catches people out.

An unapproved drug is illegal to sell. There is a second, separate problem called misbranding, which means the label is missing something it is required to have. One of those required things is directions telling a person how to use it.

A vial labelled "not for human consumption" carries no directions for human use, by design. So if the FDA decides it was meant for people anyway, those missing directions become a second problem rather than a defence.⁴

The label was supposed to be the shield. It ends up as part of the case.

The compounding track

The second question runs on a completely different set of rules.

Compounding pharmacies make preparations that are not FDA-approved products, under sections 503A and 503B. What they can use is governed by lists. Category 1 is substances that may be used while under evaluation. Category 2 is substances the FDA has flagged as presenting significant safety risks, which pharmacies may not use.

People trip on the same three things here.

Being removed from Category 2 does not make something legal. In April 2026, twelve peptides including BPC-157 came off the Category 2 list. They did not move onto the approved list. They landed in between, which is not a permission.

An advisory committee recommendation is not a decision. In July 2026, a committee voted to recommend adding several peptides, including BPC-157 and TB-500, to the list pharmacies may use. The FDA's own scientific reviewers had advised against them. A recommendation is advice. The FDA would then have to write formal rules, twice, in draft and then final form, before anything actually changes.⁵

Five more peptides go before the same committee by the end of February 2027.

Compoundable is not approved. Even at the end of that process, it would mean a licensed pharmacy could make it on a prescription. It would not mean anyone had shown it works.

Sermorelin is the compound that makes this track visible. It stayed in Category 1 when nineteen others moved to Category 2, so a pharmacy can legally compound it while ipamorelin, sold beside it and often in the same vial, cannot.

Where you got it changes the answer

The same molecule arrives through four channels with four different legal positions, and people routinely assume a clinic setting makes something legal. It does not.

A research chemical vendor sells under "research use only" labelling. Nothing about the product was required to be tested for human use, and if the compound is unapproved and meant for people, the sale is the seller breaking the law.

A compounding pharmacy works from the permitted list under sections 503A or 503B, with a prescription. This is the only channel with a genuinely lawful path, and only for compounds on that list. Sermorelin qualifies. Ipamorelin does not, whoever is handing it to you.

A med spa or wellness clinic is the one that fools people, because the setting looks medical. A treatment room, a white coat and an intake form do not change what the compound is. When Eli Lilly filed suit in August 2026 over black-market retatrutide, the defendants included a cosmetic centre and a pharmacy alongside the peptide vendors.

A telehealth service varies enormously. Some are genuinely prescribing approved drugs or working with compounding pharmacies within the rules. Others are a website with a questionnaire attached to the same grey supply as everyone else. The compound tells you more than the packaging does.

The useful test is not how professional it looks. It is whether the compound is one a pharmacy may lawfully compound, and whether an actual prescription exists.

Importing

There is a personal importation policy, and it exists, and peptides almost never qualify for it.

It is a choice the FDA makes rather than a right you have, and the conditions are narrow. Roughly, all of these have to be true:

• The drug treats a serious condition.
• Nothing comparable is available in the US.
• It does not carry an unreasonable risk.
• The amount is around three months' supply or less.
• You can name a US-licensed doctor supervising your care.⁶

Set a research-chemical order against that list. No prescription, no supervising physician, no unavailable-treatment argument. It does not come close, and that is before the shipment reaches a border where import alerts let customs hold a package without opening it.⁷

One thing worth being clear about, because it cuts against intuition.

Purity does not affect whether it can enter the country. A vial that is 99% pure and one that is 60% pure are turned back the same way, because the question at the border is approval and labelling, not quality. A good COA does not make an unapproved drug legal to import. It tells you what is in the vial, which is a different and still worthwhile thing.

And the question you actually asked

Is it illegal to have peptides for yourself.

The honest answer has three parts and none of them is a clean yes or no.

The rules are aimed at sellers. This law was built to control the people making, shipping and selling, not the people buying. Peptides are not scheduled under the Controlled Substances Act the way that controlled drugs are, so there is no possession offence in the way people picture.¹

One peptide is an exception. Human growth hormone carries criminal exposure for distribution under its own federal statute, and several states schedule it outright. Our guide on peptides and steroids covers where that line sits.

Still not the same as legal. Having some yourself is rarely something federal authorities go after, and "rarely goes after" is not a category the law actually has. It is a description of what tends to happen, and it can change.

Importing is a separate act with a separate answer. Bringing an unapproved drug into the country is not legal regardless of quantity or personal intent. In practice what happens to an individual is usually that the package gets seized, rather than anything worse, and quantity matters: amounts that look like distribution invite a different kind of attention.

So: buying it is the seller's violation, having it is a grey area nobody has properly tested, and importing it is technically unlawful with mild usual consequences. Anyone telling you it is definitely fine, or definitely a crime, is flattening something that genuinely is not flat.

The fifth question: tested sport

If you compete under any anti-doping code, this section matters more than everything above it, because it is the one with a track record of actual consequences.

BPC-157 was added to the WADA Prohibited List by name in January 2022, under S0, non-approved substances. Thymosin beta-4 and its derivatives have been listed under S2.3, growth factors, since 2018, with TB-500 named as the example. CJC-1295 falls under S2.2, growth hormone releasing factors.⁹

All are prohibited at all times, in and out of competition. All sit in the category that carries a standard four-year ban for a first offence.

People get the same three things wrong about this.

The FDA and WADA are unrelated systems. The April 2026 removal of BPC-157 from a compounding list changed its US regulatory position and had no effect on its anti-doping status. A compound can become easier to obtain lawfully in a pharmacy and remain a four-year ban in sport, because the two systems are answering different questions.¹⁰

No therapeutic use exemption is available for a non-approved substance. The exemption process exists for approved medicines with a legitimate clinical need. You cannot get one for a compound no clinician can lawfully prescribe.

"It will not show on a standard test" is not protection. A ban does not require a failed lab test. Admissions, possession, and purchase records are enough on their own, and athletes have been banned on exactly that basis with no failed test. A Canadian athlete received four years for a case built without a failed test, involving both BPC-157 and TB-500.⁹

Worth watching separately: semaglutide and tirzepatide currently sit on WADA's monitoring programme, which is the step that sometimes precedes prohibition. A decision on whether GLP-1 drugs join the list is expected before the 2028 Games.¹⁰

Everywhere else

This page describes United States law. The picture elsewhere is not milder.

Australia is the sharpest example. Most peptides sit in Schedule 4, prescription only, or Schedule 9, prohibited, and importing without a prescription and a permit carries penalties far beyond anything an American buyer faces. Australia's medicines regulator cited the WADA prohibition as supporting evidence when it scheduled BPC-157, which is a useful demonstration that these systems inform one another.¹¹

The broader point is that a compound's status does not travel. Something purchased lawfully in one country can be seized entering another, and a foreign prescription generally does not help. If you are outside the US, treat everything on this page as background and check your own regulator.

What this means when you are reading a product page

Three practical things follow.

"Research use only" tells you about the seller's legal posture, not about the product. It is not a quality mark, a safety classification, or a signal that anyone checked anything. It means nobody was required to check.

A vendor making strong claims about what a compound does to people is taking on more risk than one that keeps its wording plain. Not moral risk. The risk of being shut down, which becomes your problem when a site vanishes with your order. Quiet, technical product copy is a better sign than confident claims about tendons and metabolism.

Legal status and quality are independent. A compound can be perfectly legal and poorly made, or illegal and immaculate. These are two separate things to check and most people check neither.

Common questions

Are peptides illegal?

Most unapproved peptides are illegal to sell for human use, and that is where the attention goes. Whether it is illegal for an individual to possess one is a different and much less settled question. Approved peptides like semaglutide are ordinary prescription medicines.

Does "research use only" make it legal?

No. Under the FD&C Act a product is a drug based on intended use, and the FDA reads intended use from the whole context: the claims on the page, the dosing instructions, the syringes sold alongside, the testimonials. The disclaimer is one piece of evidence against all of that, and it usually loses.

Is BPC-157 legal now that it came off the FDA list?

No. The April 2026 removal from Category 2 did not authorise anything, and the July 2026 advisory committee vote was a recommendation rather than a decision. The FDA would have to write formal rules first. Compounding it is still not permitted, and it is not an approved drug for any use.

Can I get in trouble for buying peptides?

The rules are aimed at sellers. Individual possession is not a federal priority and is not explicitly legal either. Importing from overseas is technically unlawful even for personal use, and the usual consequence for an individual is a seized package. Larger quantities change the picture.

Can my doctor prescribe a research peptide?

Not an unapproved one. A doctor cannot legally prescribe an unapproved drug, and a compounding pharmacy can only work from the approved list. Sermorelin sits on that list. Ipamorelin does not.

Does a good COA make it legal?

No, and this is worth separating carefully. A certificate of analysis tells you what is in the vial, which is genuinely useful. Whether it can legally enter the country turns on approval and labelling, not purity. A 99% pure unapproved drug is exactly as unapproved as a 60% one.

I am a tested athlete. Is any of this safe for me?

Effectively no. BPC-157 sits under S0, thymosin beta-4 and TB-500 under S2.3, and CJC-1295 under S2.2, all prohibited at all times with a standard four-year suspension for a first violation. No therapeutic use exemption is available for a non-approved substance. And a sanction does not require a failed test: admissions, possession and purchase records have been enough on their own.

Does getting it from a clinic make it legal?

Not by itself. The lawful path runs through a compounding pharmacy working from the permitted list with a prescription, and it only covers compounds on that list. A treatment room and an intake form do not change what the compound is. Lilly's August 2026 lawsuits named a cosmetic centre and a pharmacy alongside the peptide vendors.

Why is this so complicated?

Because four different questions share one word. Approval, compounding, selling and having it run on different rules, different lists and different agencies, and one compound can land in a different spot on each. Most confusion in this subject comes from an answer to one question being quoted as the answer to another.

References

1. Federal Food, Drug and Cosmetic Act section 201(g)(1), codified at 21 U.S.C. 321(g)(1), and section 505(a), codified at 21 U.S.C. 355(a) — Statute, read at source. Section 321(g)(1) defines a drug to include articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, and articles other than food intended to affect the structure or any function of the body. Section 355(a) provides that no person shall introduce or deliver for introduction into interstate commerce any new drug unless an approval is effective with respect to it. Text of section 355 current to 29 December 2025. ↩
2. FDA Warning Letters database, filtered to online peptide sellers, 2024 to 2026. *Regulatory documents. Evidence of intended human use cited in these letters has included dosing instructions, bacteriostatic water and syringes sold alongside, customer testimonials, and product copy describing appetite, metabolic and body-composition effects.* ↩
3. FDA. Warning letter, Wholesale Peptide, 17 June 2026. *Regulatory document. Concerns Prostamax and Gonadorelin. States that despite "RESEARCH USE ONLY" labelling, website evidence establishes the products are intended to be drugs for human use.* ↩
4. FD&C Act section 502(f)(1), codified at 21 U.S.C. 352(f)(1). *Statute. A drug lacking adequate directions for use is misbranded, which is a violation separate from being unapproved.* ↩
5. FDA. Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026. *Regulatory document. Non-binding recommendation.* ↩
6. FDA Regulatory Procedures Manual, Chapter 9, section 9-2, Coverage of Personal Importations. *Regulatory guidance. Discretionary enforcement policy, not a legal right. Conditions include a serious condition, no comparable domestic treatment, roughly a three-month supply, and a named US-licensed physician overseeing care.* ↩
7. FDA Import Alerts index covering unapproved peptides. *Regulatory mechanism. Permits detention without physical examination at ports of entry, placing the burden on the importer to establish admissibility.* ↩
8. World Anti-Doping Agency Prohibited List, and USADA advisory on BPC-157. *Regulatory documents. BPC-157 named under S0 from January 2022; thymosin beta-4 and derivatives under S2.3 from 2018; CJC-1295 under S2.2. All prohibited at all times as non-specified substances, carrying a standard four-year sanction.* ↩
9. WADA Monitoring Program, 2026 list. *Regulatory document. Semaglutide and tirzepatide are monitored rather than prohibited. Anti-doping status is set independently of FDA compounding decisions.* ↩
10. Therapeutic Goods Administration scheduling decision on BPC-157, Advisory Committee on Medicines Scheduling, 2024. *Regulatory document. Cited the WADA prohibition as supporting evidence.* ↩